Why the study?
Targeting lipid-modulating genes such as ANGPTL3 via gene editing offers hope for a permanent solution to lower cardiovascular disease risks associated with hypercholesterolemia.
Key points are not available for this paper at this time.
Population
Mice
Comparison
Dual AAV9-mediated delivery of AncBE4max targeting Angptl3
Design
Animal experimental study
Follow-up
4 weeks
No takes yet. Share an insight, caveat, or question.
May enable durable ANGPTL3 silencing for hypercholesterolemia; leaves open clinical translation from preclinical models.
Zuo et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: